SPOTLIGHT -
EP. 1: The Immune System and Cancer Pathogenesis
EP. 2: Immunotherapy Modalities: Checkpoint Inhibitors and Vaccines
EP. 3: Adoptive Cell Therapy and Antibodies
EP. 4: PD-1 Inhibitor Use in Advanced Lung Cancer
EP. 5: PD-1 Inhibitor Use in Kidney and Bladder Cancers
EP. 6: PD-1 Inhibitor Use in Melanoma
EP. 7: The FDA Approval of Atezolizumab in Bladder Cancer
EP. 8: Combined Targeting Against VEGF and PD-1 in Bladder Cancer
EP. 9: The Emergence of PD-L1 Inhibitors
EP. 10: Immunotherapy in Novel Settings
EP. 11: Optimal Duration of Immunotherapy
EP. 12: Managing Immunotherapy-Related Toxicity
EP. 13: Oncolytic Viruses: Melanoma and Bladder Cancer
EP. 14: The Next Wave in Checkpoint Inhibition
EP. 15: Final Thoughts on Immunotherapy
Long-Term HRQOL Remains Unimpaired With HIPEC Plus Cytoreductive Surgery in Newly Diagnosed Ovarian Cancer
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
